Quantinno Capital Management LP Has $1.92 Million Position in Omnicell, Inc. $OMCL

Quantinno Capital Management LP lifted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 390.2% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 57,560 shares of the company’s stock after purchasing an additional 45,817 shares during the period. Quantinno Capital Management LP owned 0.13% of Omnicell worth $1,921,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in OMCL. Raymond James Financial Inc. acquired a new position in Omnicell during the 2nd quarter worth about $26,000. Clearstead Advisors LLC increased its position in Omnicell by 12,180.0% in the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after acquiring an additional 1,218 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new stake in Omnicell in the 4th quarter valued at about $58,000. Parkside Financial Bank & Trust raised its stake in shares of Omnicell by 1,708.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock worth $61,000 after acquiring an additional 1,264 shares during the last quarter. Finally, First Horizon Corp lifted its position in shares of Omnicell by 54.6% during the fourth quarter. First Horizon Corp now owns 1,597 shares of the company’s stock worth $72,000 after purchasing an additional 564 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the sale, the executive vice president directly owned 154,785 shares of the company’s stock, valued at $6,689,807.70. The trade was a 1.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the completion of the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at $4,874,481.26. This represents a 4.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.92% of the company’s stock.

Analysts Set New Price Targets

OMCL has been the topic of several research analyst reports. Wells Fargo & Company decreased their price target on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Craig Hallum reaffirmed a “buy” rating and set a $55.00 price objective on shares of Omnicell in a report on Wednesday, April 29th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Omnicell in a research report on Tuesday, August 4th. KeyCorp lowered their target price on Omnicell from $70.00 to $65.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Finally, Piper Sandler restated an “overweight” rating and set a $45.00 target price (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Omnicell has an average rating of “Moderate Buy” and a consensus target price of $57.86.

Omnicell Trading Down 1.2%

OMCL opened at $36.86 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. The company has a market cap of $1.68 billion, a price-to-earnings ratio of 43.88, a price-to-earnings-growth ratio of 1.02 and a beta of 0.98. The firm has a 50 day simple moving average of $41.05 and a 200 day simple moving average of $40.36. Omnicell, Inc. has a fifty-two week low of $29.06 and a fifty-two week high of $55.00.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm had revenue of $312.21 million for the quarter, compared to analysts’ expectations of $310.21 million. During the same period last year, the firm earned $0.45 earnings per share. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, sell-side analysts anticipate that Omnicell, Inc. will post 1.3 earnings per share for the current year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.